

DIA-KMTC MedTech Conference – 2026

Advancing Medical Technology from Innovation to Impact

Theme: Concept to Care – Safe, Smart, and Scalable MedTech

 **May 21–22, 2026**  **O by Tamara, Thiruvananthapuram, Kerala, India**

OVERVIEW

The DIA-KMTC MedTech Conference – 2026, to be held in Kerala in collaboration with the Kerala Medical Technology Consortium (KMTC), is a focused single track, two-day conference designed to address the rapidly evolving MedTech landscape in India and globally.

Building on the momentum of the DIA MedTech Conference 2025, this conference will bring together regulators, industry leaders, innovators, clinicians, and academia to discuss the end-to-end lifecycle of Medical Devices, Digital Health Technologies, Diagnostics, Software as a Medical Device (SaMD), and Combination Products.

The program will emphasize quality, regulatory science, innovation enablement, clinical evidence, and market access, with a strong focus on practical insights, policy alignment, and future-ready capabilities

WHAT TO EXPECT

Learning Objectives

By attending this conference, participants will be able to:

- ▶ Understand current and emerging regulatory expectations for MedTech, SaMD, diagnostics, and combination products
- ▶ Gain clarity on clinical evidence, safety, performance, and lifecycle management requirements
- ▶ Explore digital transformation, AI-enabled MedTech, and data-driven decision-making
- ▶ Learn best practices in quality systems, risk management, and post-market surveillance
- ▶ Identify pathways to accelerate innovation while ensuring patient safety and compliance

Key Priority Science Topics

DIA MedTech Conference 2026 will focus on priority science and regulatory domains critical to enabling quality-driven innovation and global market access for medical devices, in vitro diagnostics, combination products, and Software as a Medical Device (SaMD). Sessions are designed to address real-world regulatory expectations, compliance challenges, and execution best practices across highly regulated markets.

- ▶ **Quality & Compliance Excellence**
- ▶ **Regulatory Pathways for Global Market Access**
- ▶ **Clinical Evidence & Performance Evaluation**
- ▶ **Risk, Safety & Human Factors Engineering**
- ▶ **Digital, Software & AI-Enabled MedTech**
- ▶ **Advanced Manufacturing & Export Readiness**
- ▶ **Business Insight, Leadership & Talent**

Together, these topics deliver a structured, end-to-end learning experience, spanning science, regulation, manufacturing, and leadership, equipping MedTech stakeholders to build trusted, globally competitive products with patient safety at the core.

Who Should Attend

The **DIA MedTech Conference 2026** is designed for professionals involved in the development, testing, regulation, and commercialization, and end users of medical devices, in vitro diagnostics, combination products, and Software as a Medical Device (SaMD).

- ▶ MedTech, Medical Device, and Diagnostics industry professionals
- ▶ Quality, Regulatory Affairs, Clinical, and R&D leaders
- ▶ Digital Health, SaMD, AI/ML solution developers
- ▶ Clinicians, biomedical engineers, and hospital technology leaders
- ▶ Start-ups, innovators, and MedTech entrepreneurs
- ▶ CDSCO and State regulatory stakeholders
- ▶ Academia, research institutions, and policy influencers

PROGRAM COMMITTEE



C. Palani Palaniappan, Ph.D
CEO, Aridica, Corporation, United States,
DIA Board Member



C. Padmakumar
Special Officer
Kerala Medical
Technology
Consortium (KMTC)



Balagopal Chandrasekhar
Chairman, Kerala State
Industrial Development
Corporation (KSIDC)



Sridevi Nagarajan, Ph.D
Founder & Director,
AyusArogya Ltd. DIA
Communities Chair for
AI in Healthcare



B. Satheesan
Director, Malabar
Cancer Centre,
Thalassery, Kerala



Sinto Poullose
Director, Iqzyme
Medtech Pvt. Ltd



Manoj A
Independent
Consultant. Former VP
& Director-Global
Product Development
and Engineering,
Terumo Penpol



Rohit Philip
Senior Program
Consultant, Kerala
Medical Technology
Consortium (KMTC)



Chetan Makam
GM, Terumo BCT;
Managing Director &
Board Chair, Terumo
Penpol



Rejeesh Girija Remesan
General Manager
(Marketing),
Kerala Medical
Technology
Consortium



Ashok Kumar Swain, MBBS, MD
General Manager-India
& Executive Director,
DIA (India)

SPEAKERS



Gregory Smith
Country Director, FDA
India, US Embassy



B.V.R. Mohan Reddy
Founder Chairman,
Cyient Group;
Chairman, Board of
Governors, IIT
Hyderabad; Founding
Director, T-Hub



Aseem Sahu
Deputy Drug Controller
(DDC), Medical Device
Division, CDSCO (HQ)



Pooja Jani
Acting International
Relations Specialist,
FDA India Office, US
Embassy



**Mohammed Y
Safirulla K, IAS**
Director, IndiaAI
Mission, MeitY,
Government of India



Mrutyunjay Suar
Chairman, BCKIC;
CEO, KIIT-TBI; Director
General III, KIIT
University



MiRa Jacobs
Head of Digital Health,
MHRA, UK



Himanshu Baid
Managing Director,
Poly Medicure Ltd



Thomas John
Managing Director,
Agappe Diagnostics



PS Chandranand
Consultant – WHO
Prequalification;
Director, Iqzyme
Medtech Pvt. Ltd.



Sreejith Viswam
Director, Innovation
Enablers, Stryker
Global Technology
Center, India



**Sarada
Jayakrishnan**
General Manager,
Terumo Penpol



Rupam Chaudhury
Global Business Head,
Medical, Lifesciences
and Healthcare, LTTS



Anju Gopan
Director Medical
Affairs, IQVIA



Adarsh Srivastava
Head of IVD Data
Insights – Data,
Analytics & Research,
Roche



Atonu Dutta
Founder and CEO,
Neujin Solutions



Jaydeep Ruparelia
Founder and CEO,
Infopercept



**Susheela Branham
K, PhD**
CEO, Bio Valley
Incubation Council

8:00 – 8:45 AM

Registration and Welcome Coffee

8:45 – 8:50 AM

Welcome Remarks from DIA [5 min]

Ashok Kumar Swain, General Manager & Executive Director – DIA (India)

8:50 – 8:55 AM

Welcome Remarks from KMTC [5 min]

C. Padmakumar, Special Officer, Kerala Medical Technology Consortium (KMTC)

8:55 – 9:10 AM

Meeting Opening Remarks by Program Chair [15 min]

Balagopal Chandrasekhar, Chairman, Kerala State Industrial Development Corporation (KSIDC)

9:10 – 9:25 AM

KNA 1: Opening Keynote Address by USFDA [15 min]

Gregory Smith, Country Director – FDA India – US Embassy, New Delhi

9:25 – 9:45 AM

KNA 2: Opening Keynote Address: Empowering Doctors, Expanding Access, Enhancing Care AI & Engineering Transforming Healthcare [20 min]

B.V.R. Mohan Reddy, Founder Chairman, Cyient Group; Chairman, Board of Governors, IIT Hyderabad; Founder Director, T-Hub

9:45 – 11:15 AM

Session 1: Quality Leadership — Building Inspection-Ready, Scalable Compliance

Session Chair: Manoj A, Independent Consultant, Former VP & Director – Global Product Development and Engineering, Terumo Penpol Pvt Ltd.

Session Focus: How to move from “audit preparation” to quality as a leadership system. Focus on ISO 13485 alignment, CAPA discipline, supplier controls, data integrity, design controls, and creating a culture where quality accelerates speed-to-market instead of slowing it down.

9:45 – 10:00 AM

S1.T1: Redefining Quality: FDA’s Alignment with ISO 13485 and Its Impact on Manufacturers [15 min]

Rupam Chaudhury, Global Business Head, Medical, Lifesciences and Healthcare, L&T Technology Services (LTTS)

10:00 – 10:15 AM

S1.T2: Beyond Compliance – Quality as a Leadership System [15 min]

Sreejith Viswam, Director – Innovation Enablers (RAQA, R&D Test Lab and R&D Operations), Stryker Global Technology Center, India

10:15 – 11:15 AM

S1.T3: Panel Discussion [60 min]

Moderator: Manoj A, Independent Consultant

Panelists: Speakers with the additional presence of:

3. Sarada Jayakrishnan, General Manager – Quality, Terumo Penpol Pvt Ltd

4. P.S. Chandranand, PhD, WHO Prequalification Consultant; Director, Iqzyme Medtech Pvt. Ltd

5. Srihariraju Manthena, Service Delivery Manager – BSI India Regulatory Services

11:15 – 11:45 AM

Tea / Coffee & Networking Break

11:45 – 1:00 PM

Session 2: Safe & Sure — Clinical Evidence & Performance Evaluation

Session Chair: Satheesan B, MS, DNB, MCh (Surg Oncology). Director, Malabar Cancer Centre (Postgraduate Institute of Oncology Sciences and Research)

Session Focus: What “good evidence” actually means—and how to generate it efficiently. Covers performance evaluation logic, clinical evidence expectations, endpoints, study design choices, and documentation that stands up to scrutiny—so you don’t over-invest where it doesn’t add value, or under-invest and get stuck.

11:45 – 12:00 PM

S2.T1: Changing Paradigms in Clinical Trials and Validation of MedTech [15 min]

Anju Gopan, MBBS, Director Medical Affairs, IQVIA

12:00 – 12:15 PM

S2.T2: Clinical Evaluation and Validation of MedTech Devices – Strengths and Challenges in India [15 min]

12:15 – 1:00 PM

S2.T3: Panel Discussion: Building Trust in MedTech – Ensuring Safety, Clinical Evidence, and Performance in India [45 min]

Moderator: Satheesan B, Director, Malabar Cancer Centre

Panelists: Speakers with the additional presence of:

3. Vivek Ahuja, MD, EVP – Global Delivery Excellence, Strategy & Growth, Eversana

4. E. Sreekumar, MVSc, PhD, Director, Institute of Advance Virology, Kerala

5. Vijayakumar Manavalan, MBBS, MS, MCh (Surg Oncology), Pro Chancellor, Yenapoya University; Former Director of KIDWAI Memorial Institute of Oncology, Bangalore

1:00 – 2:00 PM

Lunch Break

2:00 – 3:30 PM

Session 3: Navigating the AI Frontier in MedTech: From SaMD to AI-Driven Drug Development

Session Chair: Sridevi Nagarajan, Founder & Director, AyusArogya Ltd.; DIA Communities Chair for AI in Healthcare

Session Focus: *The global MedTech environment for medical AI has reached a decisive turning point. Topics addressed include SaMD classification under the EU AI Act and FDA guidance; AI applications in drug development and MedTech innovation; validation and lifecycle control for adaptive algorithms; cybersecurity obligations; post-market surveillance; and a multi-jurisdictional regulatory strategy spanning the FDA, EMA, MHRA, and CDSCO.*

2:00 – 2:15 PM

S3.T1: The Regulatory Landscape in 2026 [15 min]

Sridevi Nagarajan (Session Chair)

2:15 – 2:30 PM

S3.T2: AI in Drug Development & MedTech Innovation [15 min]

Adarsh Srivastava, Head of IVD Data Insights – Data, Analytics & Research, Roche, India

2:30 – 2:45 PM

S3.T3: Validation, Cybersecurity & Lifecycle Control [15 min]

Jaydeep Ruparelia, Founder and CEO, Infopercept

2:45 – 3:30 PM

S3.T4: Panel Discussion: Future of AI in MedTech [45 min]

Moderator: Sridevi Nagarajan

Panelists: Speakers with the additional presence of:

3. Aseem Sahu, Deputy Drug Controller (DDC), Medical Device Division, CDSCO (HQ), India

4. Rohit Philip, Senior Program Consultant, KMTC

5. MiRa Jacobs, PhD, Head of Digital Health, MHRA, UK – Virtual

6. Vivek Ahuja, MD, EVP – Global Delivery Excellence, Strategy & Growth, Eversana

3:30 – 4:00 PM

Tea / Coffee & Networking Break

4:00 – 5:30 PM

Session 4: The Regulatory Maze — Mapping Pathways to India, EU, and US Market Access

Session Chair: Sinto Poulouse, Director at Iqzyme Medtech Pvt. Ltd

Session Focus: *A practical navigation session on US FDA, EU MDR, and India's CDSCO regulatory routes—how to choose the right pathway, avoid common and avoidable delays, and build a regulatory strategy aligned with your product type, risk class, and target market timelines. Expect concrete do's and don'ts from real submissions, approval journeys, and market-entry playbooks across mature and emerging markets.*

4:00 – 4:15 PM

S4.T1: Introduction to FDA CDRH and Medical Devices [15 min]

Pooja Jani, MD, MPH, Acting International Relations Specialist, US FDA India Office, US Embassy, New Delhi – Virtual

4:15 – 4:30 PM

S4.T2: Keynote Presentation [15 min]

Aseem Sahu, Deputy Drug Controller (DDC), Medical Device Division, CDSCO (HQ)

4:30 – 5:30 PM

S4.T3: Panel Discussion [60 min]

Moderator: P.S. Chandranand, WHO Prequalification Consultant; Director, Iqzyme Medtech

Panelists: Speakers with the additional presence of:

3. **Dr. K Sujith Kumar**, Drug Controller & State Licencing Authority, Kerala

4. **Sreejith Viswam**, Director – Innovation Enablers, Stryker Global Technology Center, India

5. **Wil Vargas**, MEM, International Regulatory Policy Analyst, CDRH, US FDA - Virtual

6. **Stephanie Shedd**, **RAC, CQA**, International Regulatory Policy Analyst, CDRH, US FDA – Virtual

5:30 – 5:45 PM

Day 1 Wrap Up

AGENDA | Day 2 | Friday, 22 May 2026

9:00 – 9:05 AM

Welcome & Recap of Day 1 [5 min]

Program Chair / DIA

9:05 – 9:15 AM

KNA 1: Keynote Address: Personalized Medicine – A New Frontier: Convergence of the 4 D's: Drugs, Devices, Diagnostics & Digital [10 min]

C. Palani Palaniappan, Ph.D, CEO, Aridica Corporation, USA; DIA Global Board of Directors

9:15 – 9:30 AM

KNA 2: Keynote Address [15 min]

Mohammed Y Safirulla K, IAS, Director, IndiaAI Mission; Ministry of Electronics and Information Technology, Government of India

9:30 – 11:00 AM

Session 5: Creating a Business Leadership & Talent Ecosystem for Global MedTech

Session Chair: **Chetan Makam**, General Manager, Global Blood Solutions – Terumo Blood and Cell Technologies, and Managing Director & Board Chair – Terumo Penpol

Session Focus: *Creating a Business, Leadership & Talent Ecosystem for Global Medtech is about building what works on the ground. This session looks at how leaders design systems that scale MedTech innovations in complex, regulated markets while hard wiring resilience into supply chains for medical plastics and electronics. We will explore how to architect robust RA/QA and clinical capabilities, enable fast, fact-based decisions under uncertainty, and orchestrate cross-functional teams that deliver consistently at global scale. We will also dig into building a services and talent ecosystem—attracting, growing, and retaining people who can think beyond products, partner deeply with suppliers, de-risk critical component and create an ecosystem into sustainable competitive advantage in MedTech.*

9:30 – 9:45 AM

S5.T1: Helping Build the Bio/MedTech/Life Sciences Ecosystem [15 min]

Susheela Branham K, PhD, Scientist F, CEO, Bio Valley Incubation Council, AMTZ Campus, Visakhapatnam

9:45 – 11:00 AM

S5.T2: Panel Discussion [75 min]

Moderator: **Chetan Makam**, General Manager – Terumo BCT, and MD & Board Chair – Terumo Penpol

Panelists: Speakers with the additional presence of:

2. **Dr Vibhav Garg**, President – Global Govt Affairs, Meril

3. **Mrutyunjay Suar**, CEO at KIIT-TBI; Director General Industry-Institute-Innovation-Interface at KIIT University; Chairman of BCKIC

4. **Thomas John**, Managing Director, Agappe Diagnostics Ltd

11:00 – 11:30 AM

Tea / Coffee & Networking Break

11:30 AM – 1:00 PM

Session 6: World Café — Breaking Barriers to Global MedTech Success

Session Chair: **Rohit Philip**, Senior Program Consultant, Kerala Medical Technology Consortium

Session Focus: *An outcome-led, structured discussion format to surface the real blockers across regulation, evidence, quality systems, digital trust, talent, and export readiness—and convert them into an actionable set of ecosystem recommendations. Less “panel talk,” more field intelligence + solutions capture.*

11:30 – 12:30 PM	S6.T1: Activity [60 min] All delegates
12:30 – 1:00 PM	S6.T2: Presentation by each Facilitator [30 min] The Table Facilitators
1:00 – 2:00 PM	Lunch Break
2:00 – 3:30 PM	Session 7: Manufacturing as the Secret Weapon — Advanced Manufacturing & Export Readiness Session Chair: C. Padmakumar , Special Officer, Kerala Medical Technology Consortium (KMTC) Session Focus: <i>Manufacturing maturity is a market access advantage. Covers process validation, tech transfer, supplier qualification, traceability, scale-up discipline, and how to translate manufacturing strength into regulatory confidence and buyer trust—especially for export markets.</i>
2:00 – 2:15 PM	S7.T1: From Low-Cost to World-Class: The Hard Truth About Competing in Global MedTech [15 min] Himanshu Baid , Managing Director, Poly Medicure Ltd
2:15 – 2:30 PM	S7.T2: Importing Medical Devices: FDA Overview and Common Issues [15 min] CDR Neil Bonzagni, PhD, MPH , Acting Deputy Director, US FDA India Office, US Embassy, New Delhi – Virtual
2:30 – 3:30 PM	S7.T3: Panel Discussion [45 min] Moderator: C. Padmakumar , Special Officer, KMTC Panelists: Speakers with the additional presence of: 3. B. Harikrishnan , General Manager, Terumo Penpol 4. Aniraj Radhakrishnan , General Manager, SFO Technologies 5. Mohammed Y Safirulla K, IAS , Director, IndiaAI Mission; Ministry of Electronics and Information Technology, Government of India
3:30 – 4:00 PM	Session 8: Moonshot: Democratizing Assistive Hearing Technology Session Facilitator: C. Padmakumar , Special Officer, KMTC, Rejeesh GR , General Manager (Marketing), Kerala Medical Technology Consortium Session Focus: <i>The Kerala Medical Technology Consortium presents the Hearing Aid Moonshot Project—a bold pan-India initiative to design, validate, and manufacture a world-class, affordable digital hearing aid for the millions who need it most. Inspired by Aravind Eye Care's revolution in vision care and Narayana Health's model in cardiac medicine, this initiative brings that same spirit of accessible excellence to hearing health. India's aging population—rural and urban alike—faces a growing, largely silent crisis of hearing dysfunction, yet quality hearing aids remain out of reach for the vast majority. By uniting expertise across engineering, clinical sciences, and industrial production, the Consortium aims to close this critical gap while positioning India as a global player in assistive technology and MedTech innovation. This is not merely a product initiative. It is a movement toward hearing equity.</i>
4:00 – 4:15 PM	Closing Remarks & Vote of Thanks Program Chair, KMTC and DIA
4:15 – 5:30 PM	High Tea, Networking & Conference Close <i>Wind down over high tea, catch up with peers, and make a few last connections. A relaxed close to the conference before we head out.</i>

Strategic Partner



Media Partner



PAYMENT INFORMATION

Meeting registration for an individual participant with **ONLINE payment** can be completed directly through the DIA website meeting [Registration](#) page.

For group registrations, please contact the meeting manager (below table).

BANK ACCOUNT details for other modes of payment:

Account Name: DIA (INDIA) PRIVATE LIMITED
Account No: 061010200024611
Bank Name: AXIS BANK LIMITED
Branch Name: Dhiraj Baug, Near Hari Niwas Circle,
LBS Marg, Thane (W) – 400602
IFSC Code: UTIB0000061 MICR Code: 400211013
Swift Code: AXISINBB061

Add Membership for Instant Discounts

Join DIA today to enjoy discounted meeting registration fees and unlock all membership benefits. Visit www.diaglobal.org and select the “Membership” option under the “Get Involved” tab for more details.

Select the ‘Add Membership’ option during registration to instantly avail membership discount on the registrations fee.

CHEQUE / DRAFT

Completed form, along with draft/cheque made payable to DIA (India) Private Limited should be sent to:

Vinita Shetty | Finance Manager
DIA (India) Pvt. Ltd.
Cowork30, Office #201, ACME Plaza-2, Chakala
Andheri- Kurla Road, Andheri (East), Mumbai – 400059
Email: vinita.shetty@diaglobal.org Cell: +91 9769764645

PRIVACY POLICY

DIA respects the privacy of all its members and customers. To view our policy, click the link below: <https://www.diaglobal.org/en/about-us/privacy-policy>. You agree that your personal data will be transferred to DIA in the US.

*Academia Category

The ACADEMIA category applies to individuals with primary, full-time affiliation to a bona fide academic institution, and includes STUDENTS. Proof of appointment or enrollment is required.

REGISTRATION FEES

Category	Advance Rate until (30 th April)	Standard Rate 1 st May onwards
Industry – Member	INR 10,500 + GST	INR 13,000 + GST
Industry – Non-Member	INR 13,000 + GST	INR 15,000 + GST
Academia*/ Non-Profit / Govt – Member	INR 5,000 + GST	DIA Membership Fee Discounts: 71% off for students (₹ 1,970 + GST) 50% off for academia/government (₹ 3,397 + GST)
Academia*/ Non-Profit / Govt – Non-member	INR 8,000 + GST	

For Group Registrations: Please contact meeting manager. Email: nishank.nivedit@diaglobal.org | Mob: +91 8178837734

DIA Cancellation & Refund Policy :

- Cancellation Deadline:** Cancellations must be submitted in writing and received by **20th April 2026** to qualify for a refund. Cancellations received after this date will not be eligible for any refund.
- No-Shows and Late Cancellations:** Registrants who do not cancel writing by the deadline and do not attend the event will remain liable for the full registration fee. No refunds will be issued under such circumstances.
- Administrative Fee:** A 25% administrative fee will be deducted from all eligible refunds.
- Force Majeure:** DIA reserves the right to alter the venue or the date. In the event of cancellation or postponement due to circumstances beyond DIA's control (including but not limited to natural disasters, public health emergencies, government restrictions, or strikes), DIA shall not be held liable for any resulting costs or damages, and refunds may be partially or fully waived at DIA's discretion.
- Travel and Accommodation Liability:** DIA is not responsible for any airfare, hotel, or travel-related expenses incurred by participants. These arrangements are the sole responsibility of the registrant.
- Refund Processing and Currency Disclaimer:** Eligible refunds will be processed within 60 business days after the conclusion of the event. Refunds will be made in the original transaction currency, and DIA will not be liable for any bank charges or currency fluctuations.

DIA REGISTRATION FORM

PLEASE PRINT ALL INFORMATION CLEARLY

Dd Month 2025

Please check the applicable category: Industry Government Academia Student

Last Name

First Name

Middle Initial

Please check one:

Mr. Ms. Dr. Prof.

Job Position

Name of Organization (Primary Affiliation)

Address: (As per your country's format))

City

Postal Code

Country

Home
 Business

Mobile Number (Required)

Telephone Number

Email (Required for confirmation)

If sending this form by post or courier, please provide a copy of the registrant's business card.